A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 3
- Sponsors Bayer
- 12 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2018 Status changed from not yet recruiting to recruiting.
- 19 Jan 2018 New trial record